Insmed (NASDAQ:INSM) Trading Down 5.9% - What's Next?

Key Points

• Shares fell 5.9% to about $135.34 mid-day Friday, with trading volume roughly 1.28M shares (down ~47% from the average session volume).
• Analysts remain broadly positive, with an average rating of "Buy" and an average price target of $213.23; several firms have recently upgraded or raised targets (e.g., Barclays $237, Morgan Stanley $212).
• Fundamentals are mixed: Insmed missed quarterly EPS (-$1.54 vs. -$1.07 estimate) despite revenue up 152.6% year-over-year, and insiders have sold about $28.25M of stock in the past 90 days.

Shares of Insmed, Inc. (NASDAQ:INSM - Get Free Report) traded down 5.9% during mid-day trading on Friday . The stock traded as low as $135.69 and last traded at $135.3350. 1,277,904 shares were traded during trading, a decline of 47% from the average session volume of 2,404,960 shares. The stock had previously closed at $143.83.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the company. Barclays lifted their price objective on Insmed from $231.00 to $237.00 and gave the stock an "overweight" rating in a report on Wednesday, April 1st. UBS Group reduced their price objective on Insmed from $223.00 to $215.00 and set a "buy" rating for the company in a report on Tuesday, January 6th. Raymond James Financial began coverage on Insmed in a research report on Friday, April 10th. They set an "outperform" rating and a $200.00 price objective for the company. Morgan Stanley upgraded Insmed from an "equal weight" rating to an "overweight" rating and lifted their price objective for the stock from $166.00 to $212.00 in a research report on Monday, March 30th. Finally, Truist Financial set a $205.00 price objective on Insmed in a research report on Monday, January 12th. Two analysts have rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Buy" and an average target price of $213.23.

Insmed Price Performance

The company has a fifty day simple moving average of $149.54 and a two-hundred day simple moving average of $167.10. The company has a debt-to-equity ratio of 0.76, a quick ratio of 3.54 and a current ratio of 3.83. The company has a market capitalization of $29.32 billion, a price-to-earnings ratio of -21.13 and a beta of 1.10.

Insmed (NASDAQ:INSM - Get Free Report) last issued its quarterly earnings results on Thursday, February 19th. The biopharmaceutical company reported ($1.54) earnings per share for the quarter, missing the consensus estimate of ($1.07) by ($0.47). The business had revenue of $263.84 million during the quarter, compared to analyst estimates of $263.97 million. Insmed had a negative net margin of 210.54% and a negative return on equity of 168.36%. The company's revenue was up 152.6% on a year-over-year basis. During the same quarter last year, the firm posted ($1.32) earnings per share. As a group, research analysts anticipate that Insmed, Inc. will post -2.51 earnings per share for the current year.

Insider Transactions at Insmed

In other news, COO Roger Adsett sold 88,060 shares of the company's stock in a transaction on Wednesday, April 1st. The stock was sold at an average price of $164.63, for a total transaction of $14,497,317.80. Following the completion of the sale, the chief operating officer directly owned 106,810 shares in the company, valued at $17,584,130.30. This represents a 45.19% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, insider Michael Alexander Smith sold 19,638 shares of the company's stock in a transaction on Monday, March 30th. The stock was sold at an average price of $150.98, for a total value of $2,964,945.24. Following the sale, the insider owned 51,871 shares of the company's stock, valued at approximately $7,831,483.58. The trade was a 27.46% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 179,777 shares of company stock worth $28,252,720 in the last ninety days. Insiders own 2.10% of the company's stock.

Institutional Trading of Insmed

Institutional investors have recently added to or reduced their stakes in the business. CIBC Private Wealth Group LLC boosted its position in Insmed by 42.1% during the 3rd quarter. CIBC Private Wealth Group LLC now owns 179 shares of the biopharmaceutical company's stock worth $26,000 after purchasing an additional 53 shares during the period. CoreCap Advisors LLC purchased a new position in Insmed in the 4th quarter valued at about $27,000. Stone House Investment Management LLC purchased a new position in Insmed in the 3rd quarter valued at about $29,000. SBI Securities Co. Ltd. boosted its position in Insmed by 404.9% in the 3rd quarter. SBI Securities Co. Ltd. now owns 207 shares of the biopharmaceutical company's stock valued at $30,000 after buying an additional 166 shares during the last quarter. Finally, GraniteShares Advisors LLC acquired a new stake in shares of Insmed in the 4th quarter valued at about $30,000.

Insmed Company Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company's principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.